Patents Assigned to Amgen
  • Anti-mesothelin binding proteins
    Patent number: 10919975
    Abstract: The present disclosure provides compositions and methods relating to antigen binding proteins, in particular, antibodies and bispecific antibodies which specifically bind to mesothelin. The disclosure provides nucleic acids encoding such antigen binding proteins and antibodies and methods of making and using such antibodies, including methods of treating and preventing cancer or other hypoproliferative disorders and related disorders by administering such antigen binding proteins and antibodies to a subject in need of such treatment.
    Type: Grant
    Filed: September 6, 2018
    Date of Patent: February 16, 2021
    Assignee: AMGEN INC.
    Inventors: William Christian Fanslow, III, Carl Kozlosky, Jean Marie Gudas
  • COMPOUNDS THAT INHIBIT MCL-1 PROTEIN
    Publication number: 20210040120
    Abstract: Provided herein are compounds that are useful intermediates that may used to synthesize myeloid cell leukemia 1 protein (Mcl-1) inhibitors. Also provided are Mcl-1 inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.
    Type: Application
    Filed: October 21, 2020
    Publication date: February 11, 2021
    Applicant: AMGEN INC.
    Inventors: Brian S. LUCAS, Nick A. PARAS
  • DKK1 ANTIBODIES AND METHODS OF USE
    Publication number: 20210040189
    Abstract: The present invention provides antibodies and immunologically functional fragments thereof that specifically bind DKK1 polypeptides. Methods for preparing such antibodies or fragments thereof as well as physiologically acceptable compositions containing the antibodies or fragments are also provided. Use of the antibodies and fragments to treat various diseases are also disclosed.
    Type: Application
    Filed: September 9, 2020
    Publication date: February 11, 2021
    Applicant: AMGEN INC.
    Inventors: William Gleason RICHARDS, Hsieng Sen LU, Hua Zhu KE, Chaoyang LI, Frederick W. JACOBSEN
  • METHODS FOR THE PREPARATION OF TRYPSIN-RESISTANT POLYPEPTIDES FOR MASS SPECTROMETRIC ANALYSIS
    Publication number: 20210041453
    Abstract: The disclosed methods are directed to preparing and detecting polypeptides using neutrophil elastase, such as human neutrophil elastase. The polypeptides are optionally denatured, reduced, and/or alkylated before being subjected to a first digestion. A second digestion comprises the use of neutrophil elastase, such as human neutrophil elastase. The prepared fragments are then analyzed chromatographically, electrophoretically, or spectrometrically, or a combination of these methods. The methods are especially useful for the preparation of therapeutic polypeptides for analysis, especially those that are not easily cleaved, such as some bi-specific T-cell engager (BiTE®) molecules.
    Type: Application
    Filed: March 12, 2019
    Publication date: February 11, 2021
    Applicant: Amgen Inc.
    Inventors: Sabrina Amelle BENCHAAR, Andrew DYKSTRA
  • Method for determining whether a peptide comprises aspartate or isoaspartate
    Patent number: 10908165
    Abstract: The invention generally relates to methods for determining whether a peptide includes aspartate or isoaspartate. In certain aspects, methods of the invention involve binding an aspartate/isoaspartate residue in a peptide with a label to produce a labeled peptide. The labeled peptide is then ionized. The ionizing process causes the label to undergo rearrangement in a gas phase at a higher rate if the label is bound to the aspartate residue as compared to if the label is bound to the isoaspartate residue. The methods of the invention then involve performing a mass spectrometry analysis to detect the rearrangement of the label, thereby determining whether the peptide includes aspartate or isoaspartate.
    Type: Grant
    Filed: June 7, 2018
    Date of Patent: February 2, 2021
    Assignees: Purdue Research Foundation, AMGEN INC.
    Inventors: Stephen T. Ayrton, Robert Graham Cooks, Tawnya Flick, Da Ren
  • Method of treating or ameliorating metabolic disorders using GLP-1 receptor agonists conjugated to antagonists for gastric inhibitory peptide receptor (GIPR)
    Patent number: 10905772
    Abstract: Methods of treating metabolic diseases and disorders using a composition comprising an antigen binding protein specific for the GIPR polypeptide conjugated to a GLP-1 receptor agonist are provided. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy. In certain embodiments the composition comprises an antibody or functional fragment thereof comprising a cysteine at one or more conjugation site(s) wherein the GLP-1 receptor agonist is conjugated to the antibody or functional fragment thereof through the side-chain of the cysteine residue.
    Type: Grant
    Filed: January 16, 2018
    Date of Patent: February 2, 2021
    Assignee: Amgen Inc.
    Inventors: Yuan Cheng, Chawita Netirojjanakul, Jerry Ryan Holder, Bin Wu, James R. Falsey, Bradley J. Herberich, Kelvin Sham, Leslie P. Miranda, Shu-Chen Lu, Murielle M. Veniant-Ellison, Shanaka Stanislaus, Junming Yie, Jing Xu
  • Overexpression of n-glycosylation pathway regulators to modulate glycosylation of recombinant proteins
    Patent number: 10907186
    Abstract: Methods of modulating the properties of a cell culture expressing a protein of interest are provided. In various embodiments the methods relate to the overexpression of proteins involved in the N-glycosylation pathway.
    Type: Grant
    Filed: May 15, 2020
    Date of Patent: February 2, 2021
    Assignee: Amgen Inc.
    Inventors: Shivani Gupta, Sohye Kang
  • Triazole phenyl compounds as agonists of the APJ receptor
    Patent number: 10906890
    Abstract: Compounds of Formula I and Formula II, pharmaceutically acceptable salt thereof, stereoisomers of any of the foregoing, or mixtures thereof are agonists of the APJ Receptor and may have use in treating cardiovascular and other conditions. Compounds of Formula I and Formula II have the following structures: (I), (II) where the definitions of the variables are provided herein.
    Type: Grant
    Filed: November 3, 2017
    Date of Patent: February 2, 2021
    Assignee: AMGEN INC.
    Inventors: Ning Chen, Yinhong Chen, Mikkel V. Debenedetto, Paul John Dransfield, James S. Harvey, Julie Anne Heath, Jonathan Houze, Aarif Yusuf Khakoo, Su-Jen Lai, Zhihua Ma, Nobuko Nishimura, Vatee Pattaropong, Gayathri Swaminath, Wen-Chen Yeh, Charles Kreiman
  • Bisamide sarcomere activating compounds and uses thereof
    Patent number: 10899746
    Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising a compound of the invention, a method for manufacturing compounds of the invention and therapeutic uses thereof.
    Type: Grant
    Filed: March 27, 2020
    Date of Patent: January 26, 2021
    Assignees: AMGEN INC., CYTOKINETICS, INC.
    Inventors: Luke Ashcraft, Alessandro Boezio, John Butler, Aroop Chandra, Chihyuan Chuang, Scott E. Collibee, Mikkel V. Debenedetto, Vincent DiMassa, Russell Graceffa, Justin Malinowski, David Moebius, Bradley Paul Morgan, Joshua Payette, Antonio Romero, David St. Jean, Jr., Richard Vargas, John Yeoman, Hanmo Zhang, Alan Cheng, Felix Gonzalez Lopez De Turiso, Michael Garrett Johnson
  • PROCESS FOR MANIPULATING THE LEVEL OF GLYCAN CONTENT OF A GLYCOPROTEIN
    Publication number: 20210017565
    Abstract: The present invention provides a method for manipulating the fucosylated glycan content on a recombinant protein.
    Type: Application
    Filed: October 2, 2020
    Publication date: January 21, 2021
    Applicant: AMGEN INC.
    Inventors: Daniel R. LEISKE, Michael T. TRENTALANGE
  • METHODS OF TREATMENT WITH PEGFILGRASTIM AND ROMIPLOSTIM
    Publication number: 20210015901
    Abstract: The present invention concerns methods comprising co-administration of pegfilgrastim and romiplostim for treatment of diseases and conditions characterized by low neutrophil levels (neutropenia) and/or low platelet levels (thrombocytopenia). The present invention concerns an enhanced effect on neutrophil levels and on platelet levels resulting from co-administration of pegfilgrastim and romiplostim. The present invention further concerns a method of treating a patient who has been exposed to radiation, which comprises administering romiplostim at a dose of about 1 to about 10 ?g/kg. The invention further concerns such methods wherein a single dose of romiplostim is administered to the patient and wherein romiplostim is administered about 24 hours or less after the radiation exposure. The invention further concerns treatment with romiplostim and pegfilgrastim for radiation exposure.
    Type: Application
    Filed: March 11, 2019
    Publication date: January 21, 2021
    Applicant: Amgen Inc.
    Inventors: Ganesh BALASUBRAMANIAN, Deborah I. BUNIN, Polly Y. CHANG, Simon AUTHIER, Sameer V. DOSHI, James BAKKE, Janet GAHAGEN, Karen WONG, Mark FIELDEN
  • PAC1 ANTIBODIES AND USES THEREOF
    Publication number: 20210017261
    Abstract: The present invention relates to neutralizing antibodies of the human pituitary adenylate cyclase activating polypeptide type I receptor (PAC1) and pharmaceutical compositions comprising such antibodies. Methods of treating or preventing headache conditions, such as migraine and cluster headache, using the neutralizing antibodies are also described.
    Type: Application
    Filed: July 1, 2020
    Publication date: January 21, 2021
    Applicant: AMGEN INC.
    Inventors: Neeraj Jagdish AGRAWAL, Irwin CHEN, Su CHONG, Bryna FUCHSLOCHER, Kevin GRAHAM, Agnes Eva HAMBURGER, Mark Leo MICHAELS, Christopher MOHR, Derek E. PIPER, Kenneth William WALKER, Zhulun WANG, Cen XU
  • Methods for increasing mannose content of recombinant proteins
    Patent number: 10894972
    Abstract: The present invention relates to methods of upregulating the high mannose glycoform content of a recombinant protein during a mammalian cell culture by manipulating the mannose to total hexose ratio in the cell culture media formulation.
    Type: Grant
    Filed: August 9, 2019
    Date of Patent: January 19, 2021
    Assignee: Amgen Inc.
    Inventors: Chung-Jr Huang, Xiaoming Yang
  • Growth differentiation factor 15 (GDF-15) constructs
    Patent number: 10894814
    Abstract: Constructs comprising GDF15, and mutants thereof are provided. In various embodiments the constructs comprising GDF15, and mutants thereof, can be of use in the treatment or ameliorating a metabolic disorder. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy.
    Type: Grant
    Filed: November 29, 2017
    Date of Patent: January 19, 2021
    Assignee: AMGEN INC.
    Inventors: Yumei Xiong, Yi Zhang, Jackie Z. Sheng, Agnes Eva Hamburger, Murielle M. Veniant-Ellison, Grant Shimamoto, Xiaoshan Min, Zhulun Wang, Jie Tang, Gunasekaran Kannan, Marissa Mock, Kenneth William Walker
  • Cyclopropyl fused thiazine derivatives as beta-secretase inhibitors and methods of use
    Patent number: 10889581
    Abstract: The present disclosure provides a new class of compounds useful for the modulation of beta-secretase enzyme (BACE) activity. The compounds have a general Formula I: wherein variables A, R1, R2, R2?, R3, R4, and R5 of Formula I are defined herein. This disclosure also provides pharmaceutical compositions comprising the compounds, and uses of the compounds and compositions for treatment of disorders and/or conditions related to A? plaque formation and deposition, resulting from the biological activity of BACE. Such BACE mediated disorders include, for example, Alzheimer's Disease, cognitive deficits, cognitive impairments, and other central nervous system conditions.
    Type: Grant
    Filed: December 13, 2017
    Date of Patent: January 12, 2021
    Assignee: Amgen Inc.
    Inventors: Jennifer R. Allen, Albert Amegadzie, Matthew P. Bourbeau, Jian J. Chen, Michael J. Frohn, Paul E. Harrington, Jonathan D. Low, Vu V. Ma, Thomas T. Nguyen, Alexander Pickrell, Corey Reeves
  • Thiazine derivatives as ?-secretase inhibitors and methods of use
    Patent number: 10889579
    Abstract: The present disclosure provides a class of compounds useful for the modulation of beta-secretase enzyme (BACE) activity. The compounds have a general Formula I: wherein variables R1, R1?, R2, R2?, R3, R4, R5, R6, R7, and b of Formula I are defined herein. This disclosure also provides pharmaceutical compositions comprising the compounds, and uses of the compounds and compositions for treatment of disorders and/or conditions related to A? plaque formation and deposition, resulting from the biological activity of BACE. Such BACE mediated disorders include, for example, Alzheimer's Disease, cognitive deficits, cognitive impairments, and other central nervous system conditions.
    Type: Grant
    Filed: December 13, 2017
    Date of Patent: January 12, 2021
    Assignee: Amgen Inc.
    Inventors: Matthew P. Bourbeau, Paul E. Harrington, Qingyian Liu
  • Combination therapy including an MDM2 inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers
    Patent number: 10881648
    Abstract: The present invention provides combination therapy that includes an MDM2 inhibitor and one or more additional pharmaceutically active agents, particularly for the treatment of cancers. The invention also relates to pharmaceutical compositions that contain an MDM2 inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers.
    Type: Grant
    Filed: December 21, 2018
    Date of Patent: January 5, 2021
    Assignee: AMGEN INC.
    Inventors: Sean Caenepeel, Jude Canon, Paul Hughes, Jonathan D. Oliner, Richard J. Rickles, Anne Y. Saiki
  • MAMMALIAN CELL CULTURE
    Publication number: 20200407427
    Abstract: The invention provides a method for culturing mammalian cells. The method provides greater control over cell growth to achieve high product titer cell cultures.
    Type: Application
    Filed: September 11, 2020
    Publication date: December 31, 2020
    Applicant: Amgen Inc.
    Inventors: Brian D. FOLLSTAD, Rebecca E. McCOY, Arvia E. MORRIS
  • RNAi constructs for inhibiting ASGR1 expression and methods of use thereof
    Patent number: 10870856
    Abstract: The present invention relates to RNAi constructs for reducing expression of the ASGR1 gene. Methods of using such RNAi constructs to treat or prevent cardiovascular disease, such as coronary artery disease and myocardial infarction, and to reduce serum non-HDL cholesterol levels are also described.
    Type: Grant
    Filed: August 25, 2017
    Date of Patent: December 22, 2020
    Assignee: AMGEN INC.
    Inventors: Michael Ollmann, Yang Li, Jun Zhang, Oliver Homann, Leslie P. Miranda, Justin K. Murray, Bin Wu, Oh Kyu Yoon, John Gordon Allen, Chawita Netirojjanakul
  • On-body injector
    Patent number: D905849
    Type: Grant
    Filed: November 14, 2018
    Date of Patent: December 22, 2020
    Assignee: AMGEN INC.
    Inventors: Margaux Frances Boyaval, Sigrid Moeslinger, Lisa Nugent, Brian Stonecipher, Masamichi Udagawa